Hetrombopag olamine clinical trials
A product of Hetrombopag; its studies count on that page too.
How each study uses hetrombopag olamine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the hetrombopag olamine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 9
Jiangsu HengRui Medicine Co., Ltd. (15) · Fujian Cancer Hospital (2) · RenJi Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Peking Union Medical College Hospital (1) · Sir Run Run Shaw Hospital (1) · Huazhong University of Science and Technology (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Hetrombopag
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test hetrombopag olamine.
- Dec 2026A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITPPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Jun 2027TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment TerminationPhase 2 · Peking Union Medical College Hospital
- Nov 2027Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 StudyPhase 2 · Fujian Cancer Hospital
Studies
Open first, then newest update. How each study uses hetrombopag olamine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)RecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07286032Written as Hetrombopag Olamine
- Herombopag Treated T-DM1 Induced Platelet ReductionRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07257809Written as Herombopag Olamine Tablets
- A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal CarcinomaNot yet recruitingPhase 2Fujian Cancer HospitalNCT07252375Written as herombopag olamine tablets
- Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 StudyNot yet recruitingPhase 2Fujian Cancer HospitalNCT07243418Written as herombopag olamine tablets
- A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITPRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06838949Written as herombopag olamine tablets
- TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment TerminationRecruitingPhase 2Peking Union Medical College HospitalNCT06478537Written as Hetrombopag Olamine
- Hetrombopag for the Thrombocytopenia Induced by Concurrent ChemoradiotherapyRecruitingPhase 2Sir Run Run Shaw HospitalNCT06433830Written as Hetrombopag Olamine
- Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.Not yet recruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06346925Written as Herombopag Olamine Tablets
- Study of the Food Effects of Herombopag Olamine Tablets in Healthy SubjectsNot yet recruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06062680Written as Herombopag Olamine Tablets
- Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid LeukemiaNot yet recruitingPhase 2RenJi HospitalNCT05944211Written as Hetrombopag Olamine
- Hetrombopag or Placebo in Treatment-Naive Severe Aplastic AnemiaCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT03825744Written as Hetrombopag Olamine+Standard Therapy
- Extension Study of Hetrombopag in Severe Aplastic AnemiaActive, not recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04961710Written as Hetrombopag Olamine
- A Bioequivalence Study of Hetrombopag in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05088655Written as Hetrombopag Olamine Tablet
- Herombopag Olamine in the Treatment of Thrombocytopenia After ChemotherapyStatus unknownPhase 4Huazhong University of Science and TechnologyNCT05575986Written as Hetrombopag Olamine
- Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) PatientCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT03222843Written as Hetrombopag Olamine
- A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) PatientCompletedPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT03557099Written as Hetrombopag Olamine
- An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLCStatus unknownPhase 2Henan Cancer HospitalNCT05252091Written as herombopag olamine tablets
- A Trial of Hetrombopag in Healthy and Hepatic Impairment SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05088642Written as Hetrombopag Olamine Tablet
- Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03977805Written as Hetrombopag Olamine
- A Study to Evaluate Different Intervals Between Dosing and Feeding on the PharmacokineticsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03603132Written as Hetrombopag Olamine
Codes
What other systems call hetrombopag olamine · ClinicalTrials.gg INT018197
- NCI Thesaurus C173439Hetrombopag OlamineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C173439 | Hetrombopag Olamine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.